Editas Medicine (EDIT) Prices First IPO of 2016

The first IPO for 2016 has priced.

Editas Medicine (NASDAQ: EDIT) priced its 5,900,000 share IPO at $16 per share, Bloomberg reported. This is at the low end of the expected $16-$18 range.

The offering was led by Morgan Stanley, JP Morgan, Cowen and JMP Securities.

Editas Medicine is a leading genome editing company dedicated to treating patients with genetically defined diseases by correcting their disease-causing genes. The company was founded by world leaders in genome editing, and its mission is to translate the promise of genome editing science into a broad class of transformative genomic medicines to benefit the greatest number of patients.

You May Also Be Interested In

• Editas Medicine (EDIT) to Present Pre-clinical Data Demonstrating Progression of in vivo Medicines Pipeline
• Shipbob Said To Pick Jpmorgan To Lead Ipo As Soon As Late 2024 - Bloomberg
• Viking Holdings (VIK) Announces 44M Share IPO at $21-$25/sh